Bone Solutions (BSI) announced a private label licensing agreement whereby Onkos Surgical will distribute and market OsteoCrete® magnesium-based bone void filler under the GenVie™ brand, for use in certain tumor and complex revision cases.
FDA has cleared OsteoCrete for use in bone-related surgical procedures ranging from complex injuries to all musculoskeletal extremities trauma cases.
BSI is focused on further development of bioresorbable implants and will continue to explore its applications. Earlier this month, WishBone Medical entered into a private label agreement with BSI for worldwide rights to distribute OsteoCrete for use in pediatric procedures.
Bone Solutions (BSI) announced a private label licensing agreement whereby Onkos Surgical will distribute and market OsteoCrete® magnesium-based bone void filler under the GenVie™ brand, for use in certain tumor and complex revision cases.
FDA has cleared OsteoCrete for use in bone-related surgical procedures ranging from complex...
Bone Solutions (BSI) announced a private label licensing agreement whereby Onkos Surgical will distribute and market OsteoCrete® magnesium-based bone void filler under the GenVie™ brand, for use in certain tumor and complex revision cases.
FDA has cleared OsteoCrete for use in bone-related surgical procedures ranging from complex injuries to all musculoskeletal extremities trauma cases.
BSI is focused on further development of bioresorbable implants and will continue to explore its applications. Earlier this month, WishBone Medical entered into a private label agreement with BSI for worldwide rights to distribute OsteoCrete for use in pediatric procedures.
Copy to clipboard 
